Genetic marker helps predict which MS therapy will work: Study
Researchers have identified a genetic biomarker that predicts whether people with relapsing forms of multiple sclerosis (MS) will respond to glatiramer acetate (sold as Copaxone, among others) therapy. A study based on an analysis of more than 3,000 MS patients showed that those who carry a form of…